A recent study highlights that Hormone Modulating Therapy (HMT) for breast cancer patients is associated with a 7% lower risk of developing Alzheimer’s disease and related dementia (ADRD) later in life. The research, led by Dr. Francesmary Modugno and published by the University of Pittsburgh, sheds light on the intricate relationship between breast cancer treatment and long-term brain health.

Understanding HMT and Its Benefit: HMT is primarily used to treat hormone receptor-positive breast cancer, which makes up about two-thirds of breast cancer cases. These tumours grow in response to estrogen or progesterone. HMT works by preventing these hormones from binding to their receptors, thereby slowing tumour growth. The study revealed that HMT not only aids in combating breast cancer but also offers protective benefits against dementia, especially in younger women.

Key Findings from the Stud: The study analysed data from a federal database involving women aged 65 and older diagnosed with breast cancer between 2007 and 2009. Of the 18,808 patients studied, 66% received HMT within three years of their diagnosis. The follow-up period averaged 12 years, during which it was found that 24% of HMT users developed ADRD, compared to 28% of non-HMT users.

The protective effect of HMT was most significant in women aged 65 to 69. However, this benefit diminished with age and was not observed in patients over 80. The study also highlighted racial differences in the benefits of HMT. Black women aged 65 to 74 who used HMT had a 24% reduction in ADRD risk, while white women in the same age range had an 11% reduction.

The Complexity of HMT’s Impact on Brain Health: The relationship between HMT and reduced dementia risk is influenced by multiple factors, including the type of HMT used. Different types of HMT, such as selective estrogen receptor modulators, aromatase inhibitors, and selective estrogen receptor degraders, impact estrogen in various ways. Estrogen has neuroprotective effects, and these therapies may affect ADRD risk by mimicking estrogen, affecting its production, or modulating receptor levels. HMT might also influence beta-amyloid clearance, tau protein stability, and vascular health, all linked to brain health.

Implications for Future Researc:While the study provides significant insights, it was limited to patients over 65. Future research will include younger women who haven’t reached menopause to better understand the link between HMT and dementia risk. This ongoing research aims to provide clearer guidance on HMT use and its potential long-term benefits.

The study’s findings emphasize the importance of considering individual patient factors when prescribing medications or developing treatment plans for breast cancer. HMT not only aids in managing breast cancer but also offers potential protective benefits against dementia. However, the relationship between HMT and dementia risk is complex and influenced by multiple factors, including age and race. Ongoing research is essential to further understand this association and provide comprehensive treatment guidance for breast cancer patients.

The research team, including contributors from the University of South Carolina, hopes to continue exploring the benefits of HMT and its impact on long-term health outcomes for breast cancer patients. This study highlights the need for personalized treatment plans that consider both immediate and long-term health benefits for patients.